InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: None

Tuesday, 08/15/2017 1:11:15 PM

Tuesday, August 15, 2017 1:11:15 PM

Post# of 2099
This is an accurate summary of the company line. I've always been positive on VB-111 and the latest news at the very least gives me more confidence in VB-111.

http://www.baystreet.ca/articles/research_reports/lifesci/VBL081417.pdf

The Company reiterated its guidance of having topline data in early 2018 from the Phase III GLOBE study evaluating the combination of VB-111 and Avastin (bevacizumab) for recurrent glioblastoma multiforme (rGBM). Notably, the interim analysis that was planned for the third quarter of 2017 will not occur due to the closeness of topline data, but a data safety monitoring committee (DSMC) analysis is expected to occur in late September.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News